|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dolecek TA, Propp JM, Stroup NE and
Kruchko C: CBTRUS statistical report: Primary brain and central
nervous system tumors diagnosed in the United States in 2005–2009.
Neuro Oncol. 14 Suppl 5:v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnson DR and O'Neill BP: Glioblastoma
survival in the United States before and during the temozolomide
era. J Neurooncol. 107:359–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bernfield M, Götte M, Park PW, Reizes O,
Fitzgerald ML, Lincecum J and Zako M: Functions of cell surface
heparan sulfate proteoglycans. Annu Rev Biochem. 68:729–777. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beauvais DM, Burbach BJ and Rapraeger AC:
The syndecan-1 ectodomain regulates alphavbeta3 integrin activity
in human mammary carcinoma cells. J Cell Biol. 167:171–181. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu W, Litwack ED, Stanley MJ, Langford
JK, Lander AD and Sanderson RD: Heparan sulfate proteoglycans as
adhesive and anti-invasive molecules. Syndecans and glypican have
distinct functions. J Biol Chem. 273:22825–22832. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beauvais DM and Rapraeger AC:
Syndecan-1-mediated cell spreading requires signaling by
alphavbeta3 integrins in human breast carcinoma cells. Exp Cell
Res. 286:219–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stepp MA, Daley WP, Bernstein AM,
Pal-Ghosh S, Tadvalkar G, Shashurin A, Palsen S, Jurjus RA and
Larsen M: Syndecan-1 regulates cell migration and fibronectin
fibril assembly. Exp Cell Res. 316:2322–2339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beauvais DM, Ell BJ, McWhorter AR and
Rapraeger AC: Syndecan-1 regulates alphavbeta3 and alphavbeta5
integrin activation during angiogenesis and is blocked by
synstatin, a novel peptide inhibitor. J Exp Med. 206:691–705. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Purushothaman A, Uyama T, Kobayashi F,
Yamada S, Sugahara K, Rapraeger AC and Sanderson RD:
Heparanase-enhanced shedding of syndecan-1 by myeloma cells
promotes endothelial invasion and angiogenesis. Blood.
115:2449–2457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zellweger T, Ninck C, Mirlacher M,
Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP and
Bubendorf L: Tissue microarray analysis reveals prognostic
significance of syndecan-1 expression in prostate cancer. Prostate.
55:20–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Yuan J, Zhang Z, Lin L and Xu S:
Syndecan-1 expression in human glioma is correlated with advanced
tumor progression and poor prognosis. Mol Biol Rep. 39:8979–8985.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei HT, Guo EN, Dong BG and Chen LS:
Prognostic and clinical significance of syndecan-1 in colorectal
cancer: A meta-analysis. BMC Gastroenterol. 15:1522015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anttonen A, Kajanti M, Heikkilä P,
Jalkanen M and Joensuu H: Syndecan-1 expression has prognostic
significance in head and neck carcinoma. Br J Cancer. 79:558–564.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Joensuu H, Anttonen A, Eriksson M,
Mäkitaro R, Alfthan H, Kinnula V and Leppä S: Soluble syndecan-1
and serum basic fibroblast growth factor are new prognostic factors
in lung cancer. Cancer Res. 62:5210–5217. 2002.PubMed/NCBI
|
|
16
|
Jary M, Lecomte T, Bouché O, Kim S, Dobi
E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, et al:
Prognostic value of baseline seric Syndecan-1 in initially
unresectable metastatic colorectal cancer patients: A simple
biological score. Int J Cancer. 139:2325–2335. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barbareschi M, Maisonneuve P, Aldovini D,
Cangi MG, Pecciarini L, Mauri Angelo F, Veronese S, Caffo O,
Lucenti A, Palma PD, et al: High syndecan-1 expression in breast
carcinoma is related to an aggressive phenotype and to poorer
prognosis. Cancer. 98:474–483. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsumoto A, Ono M, Fujimoto Y, Gallo RL,
Bernfield M and Kohgo Y: Reduced expression of syndecan-1 in human
hepatocellular carcinoma with high metastatic potential. Int J
Cancer. 74:482–491. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kusumoto T, Kodama J, Seki N, Nakamura K,
Hongo A and Hiramatsu Y: Clinical significance of syndecan-1 and
versican expression in human epithelial ovarian cancer. Oncol Rep.
23:917–925. 2010.PubMed/NCBI
|
|
20
|
Wiksten JP, Lundin J, Nordling S, Lundin
M, Kokkola A, von Boguslawski K and Haglund C: Epithelial and
stromal syndecan-1 expression as predictor of outcome in patients
with gastric cancer. Int J Cancer. 95:1–6. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grootjans JJ, Zimmermann P, Reekmans G,
Smets A, Degeest G, Dürr J and David G: Syntenin, a PDZ protein
that binds syndecan cytoplasmic domains. Proc Natl Acad Sci USA.
94:pp. 13683–13688. 1997, View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kegelman TP, Das SK, Hu B, Bacolod MD,
Fuller CE, Menezes ME, Emdad L, Dasgupta S, Baldwin AS, Bruce JN,
et al: MDA-9/syntenin is a key regulator of glioma pathogenesis.
Neuro Oncol. 16:50–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhong D, Ran JH, Tang WY, Zhang XD, Tan Y,
Chen GJ, Li XS and Yan Y: Mda-9/syntenin promotes human brain
glioma migration through focal adhesion kinase (FAK)-JNK and
FAK-AKT signaling. Asian Pac J Cancer Prev. 13:2897–2901. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sulka B, Lortat-Jacob H, Terreux R,
Letourneur F and Rousselle P: Tyrosine dephosphorylation of the
syndecan-1 PDZ binding domain regulates syntenin-1 recruitment. J
Biol Chem. 284:10659–10671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baietti MF, Zhang Z, Mortier E, Melchior
A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C,
Vermeiren E, et al: Syndecan-syntenin-ALIX regulates the biogenesis
of exosomes. Nat Cell Biol. 14:677–685. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parri M and Chiarugi P: Rac and Rho
GTPases in cancer cell motility control. Cell Commun Signal.
8:232010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun Z, Zhang B, Wang C, Fu T, Li L, Wu Q,
Cai Y and Wang J: Forkhead box P3 regulates ARHGAP15 expression and
affects migration of glioma cells through the Rac1 signaling
pathway. Cancer Sci. 108:61–72. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Levy-Adam F, Feld S, Suss-Toby E,
Vlodavsky I and Ilan N: Heparanase facilitates cell adhesion and
spreading by clustering of cell surface heparan sulfate
proteoglycans. PLoS One. 3:e23192008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hwangbo C, Park J and Lee JH:
mda-9/Syntenin protein positively regulates the activation of Akt
protein by facilitating integrin-linked kinase adaptor function
during adhesion to type I collagen. J Biol Chem. 286:33601–33612.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nabeshima K, Inoue T, Shimao Y and
Sameshima T: Matrix metalloproteinases in tumor invasion: Role for
cell migration. Pathol Int. 52:255–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arulanandam R, Geletu M, Feracci H and
Raptis L: Activated Rac1 requires gp130 for Stat3 activation, cell
proliferation and migration. Exp Cell Res. 316:875–886. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oyesanya RA, Bhatia S, Menezes ME, Dumur
CI, Singh KP, Bae S, Troyer DA, Wells RB, Sauter ER, Sidransky D,
et al: MDA-9/Syntenin regulates differentiation and angiogenesis
programs in head and neck squamous cell carcinoma. Oncoscience.
1:725–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Helmke BM, Polychronidis M, Benner A,
Thome M, Arribas J and Deichmann M: Melanoma metastasis is
associated with enhanced expression of the syntenin gene. Oncol
Rep. 12:221–228. 2004.PubMed/NCBI
|
|
34
|
Yang Y, Hong Q, Shi P, Liu Z, Luo J and
Shao Z: Elevated expression of syntenin in breast cancer is
correlated with lymph node metastasis and poor patient survival.
Breast Cancer Res. 15:R502013. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong D, Tang W, Wu H, Yang G and Yan Y:
Expression of syntenin in human glioma and its clinical
significance: Report of 34 cases. Di 3 Jun Yi Da Xue Xue Bao.
32:597–600. 2010.(In Chinese).
|
|
36
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
